Dr Reddy's Laboratories on Wednesday announced its consolidated financial results for the quarter ended June 30, 2023. The company reported revenue growth of 29.1 per cent YoY and 7.0 per cent QoQ to Rs. 6,758 crores and above market expectations of Rs. 6,343 crores
Read More
Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 30 June 2023, the Indian pharma giant has registered a rise of 18 per cent in its consolidated revenue to be recorded at Rs 6,465 crores in the Quarter One of Financial Year 2024 (Q1FY24) up from Rs 5,478 crores in the corresponding quarter last year
Read More
GlaxoSmithKline Pharmaceuticals(GSK) on Wednesday declared its financial results for the quarter ended June 30, 2023. Revenue from operations for the quarter grew by 1 per cent to Rs 738 crores
Read More
The Indian biopharmaceutical company Biocon saw its stocks tumble by as high as 4.58 per cent to Rs 251.90 per scrip on Monday as of 11:04 IST on the Bombay Stock Exchange (BSE) compared to the previous close of Rs 262 on Friday
Read More
Yatharth Hospital and Trauma Care Services have proposed to open its initial public offering of equity shares of face value Rs 10 each on Wednesday, July 26, 2023. The initial public offering comprises of a fresh issue of equity shares aggregating up to Rs 490 crore
Read More
Quadria will make an initial investment of roughly Rs 600 crores for an undisclosed minority stake and a further investment of up to Rs 700 crores for the additional stake, representing one of the largest investments in the eye care services space
Read More
Novavax Inc said on Friday Canada will pay USD 349.6 million to settle the forfeiting of certain doses of its COVID-19 vaccine previously scheduled for delivery. The U.S. vaccine maker also reached a deal with the country's public works and government services department to amend the advance purchase contract after a sharp decline in global demand left a raft of COVID-19 doses unused.
Read More
On Tuesday, South Korea's Samsung Biologics said that it has signed two deals with Pfizer worth around a combined 1.2 trillion won (USD 921.38 million) to manufacture products for the U.S. pharmaceutical giant
Read More
